List of Excipients in Branded Drug ADEFOVIR DIPIVOXIL

Generic Drugs Containing ADEFOVIR DIPIVOXIL

Company	Ingredient	NDC	Excipient
Sigmapharm Laboratories LLC	adefovir dipivoxil	42794-003	ANHYDROUS LACTOSE
Sigmapharm Laboratories LLC	adefovir dipivoxil	42794-003	CELLULOSE, MICROCRYSTALLINE
Sigmapharm Laboratories LLC	adefovir dipivoxil	42794-003	COPOVIDONE
Sigmapharm Laboratories LLC	adefovir dipivoxil	42794-003	CROSPOVIDONE

What are the Most Frequently-Used Excipients in ADEFOVIR DIPIVOXIL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE
1	CROSCARMELLOSE SODIUM

Adefovir Dipivoxil Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Adefovir dipivoxil is an off-patent oral nucleotide analogue used for chronic hepatitis B. Its commercial opportunity is concentrated in low-cost generic supply, regional markets, differentiated tablet platforms, and combination or pediatric presentations rather than premium branded products. The strongest formulation strategy is a simple immediate-release tablet that controls content uniformity, dissolution, stability, and manufacturing cost while avoiding excipients that complicate renal-risk positioning.

What is the regulatory and commercial status of adefovir dipivoxil?

Adefovir dipivoxil was approved by the U.S. Food and Drug Administration under NDA 021449 as Hepsera 10 mg tablets on September 20, 2002. The approved indication is treatment of chronic hepatitis B in adults with evidence of active viral replication and either persistent elevations in serum aminotransferases or histologically active disease. It is not approved as a first-line HIV treatment because of renal toxicity and the availability of better tolerated agents. [1]

Attribute	Adefovir dipivoxil
Active pharmaceutical ingredient	Adefovir dipivoxil
Active moiety	Adefovir
Original brand	Hepsera
Originator	Gilead Sciences
FDA dosage form	10 mg immediate-release tablet
Initial U.S. approval	September 20, 2002
Primary indication	Chronic hepatitis B
Administration	Once daily
Main safety constraint	Dose-related nephrotoxicity
Main commercial substitutes	Tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir
Biosimilar exposure	None; this is a small-molecule drug
Current market profile	Generic, price-sensitive, regionally concentrated

The U.S. commercial value of adefovir dipivoxil is limited by therapeutic substitution. Tenofovir and entecavir generally offer stronger antiviral efficacy or improved long-term positioning, while tenofovir alafenamide has a more favorable renal and bone safety profile than older nucleotide therapies. Adefovir remains relevant where price, formulary history, local treatment guidelines, or existing patient use support demand.

What excipients are used in Hepsera tablets?

The Hepsera tablet is an immediate-release solid oral dosage form. The U.S. prescribing information identifies the following inactive ingredients:

• Croscarmellose sodium
• Lactose monohydrate
• Magnesium stearate
• Pregelatinized starch
• Talc
• Film-coating components including hypromellose, polyethylene glycol, titanium dioxide, and iron oxide colorant

The formulation uses a conventional direct-compression or dry-granulation excipient architecture. The core is designed to disintegrate rapidly without relying on complex modified-release technology. [1]

Functional role of the reference excipients

Excipient	Primary function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low cost and widely available; creates lactose-intolerance and supplier-qualification considerations
Pregelatinized starch	Binder and disintegrant	Supports tablet strength and rapid breakup
Croscarmellose sodium	Superdisintegrant	Helps achieve immediate release at low drug load
Magnesium stearate	Lubricant	Required for manufacturing efficiency but can slow dissolution if overused
Talc	Anti-adherent and processing aid	Useful in tablet manufacture and film coating
Hypromellose	Film former	Supports coating integrity and appearance
Polyethylene glycol	Plasticizer	Reduces coating brittleness
Titanium dioxide and iron oxide	Opacifier and colorant	Supports product identification and brand differentiation

The active dose is only 10 mg, so the formulation contains a relatively high proportion of excipients. That creates a content-uniformity risk during blending. Low-dose uniformity should therefore be treated as a core development issue, not a routine scale-up parameter.

What excipient strategy is most suitable for generic adefovir dipivoxil?

The preferred commercial platform is a low-cost immediate-release tablet with robust low-dose blending and a dissolution profile closely aligned with the reference product.

1. Preserve a conventional tablet architecture

A generic developer should initially target:

• Lactose or a lactose-free alternative as the principal diluent
• Pregelatinized starch or microcrystalline cellulose as a secondary diluent and binder
• Croscarmellose sodium or sodium starch glycolate as the disintegrant
• Magnesium stearate at the lowest level that provides reliable ejection
• A thin hypromellose-based film coat

A simple formulation reduces manufacturing cost, excipient qualification burden, and regulatory comparability risk. There is limited commercial justification for a controlled-release or multiparticulate product because the reference product is once-daily and immediate release.

2. Address low-dose content uniformity

Adefovir dipivoxil is a low-dose drug. The formulation should use one of three control approaches:

1. Ordered mixing with a controlled particle-size active ingredient.
2. Wet granulation to reduce segregation.
3. Drug-layered granules or a premix for high-throughput manufacturing.

Direct blending may be economical, but it increases segregation risk if the active and excipients have materially different particle sizes, densities, or electrostatic properties. Granulation can improve uniformity but adds drying, process validation, and stability costs.

3. Control magnesium stearate exposure

Magnesium stearate can reduce wettability and delay dissolution when used at excessive concentration or mixed for too long. The formulation should use short final lubrication and dissolution testing after scale-up. This is important because adefovir dipivoxil is a prodrug whose release and conversion profile must remain reproducible.

4. Consider lactose-free positioning

A lactose-free version could support institutional tenders and patients with excipient restrictions. Suitable substitutes include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Spray-dried cellulose-based blends

Mannitol can improve mouthfeel and provide a differentiated excipient profile, but it may increase tablet weight and cost. Dibasic calcium phosphate can improve flow and compression but may alter dissolution and require tighter pH and compatibility evaluation.

5. Avoid unnecessary formulation complexity

Adefovir dipivoxil does not require a high-value delivery system for its principal indication. Lipid systems, amorphous solid dispersions, osmotic systems, and extended-release technologies would likely add cost without creating a clear clinical or commercial advantage.

What formulation patents protect adefovir dipivoxil?

The historical patent estate for adefovir includes protection around the nucleotide analogue, prodrug forms, pharmaceutical compositions, and therapeutic use. The commercially relevant U.S. exclusivity period has expired. Adefovir dipivoxil is therefore primarily a generic opportunity rather than an active branded-patent opportunity in the United States.

Protection category	Commercial assessment
Adefovir chemical entity	Historical protection; expired
Dipivoxil prodrug	Historical protection; expired in major markets
Oral tablet composition	Historical protection; no meaningful current U.S. barrier for ordinary generic development
Chronic hepatitis B method of use	Historical protection; expired or commercially ineffective against routine generic entry
Manufacturing processes	May exist in individual jurisdictions, but generally do not block standard API or tablet manufacture
Current Orange Book exclusivity	No active branded exclusivity expected for the original Hepsera product
Biosimilar pathway	Not applicable because adefovir dipivoxil is a small molecule

The relevant regulatory risk is not biosimilar competition. It is whether a generic applicant can obtain approval with acceptable pharmaceutical equivalence, dissolution, impurity control, and stability data.

When did adefovir dipivoxil lose exclusivity?

The FDA’s five-year new chemical entity exclusivity associated with the 2002 approval would have expired in 2007, subject to any applicable patent or regulatory extension. Hepsera’s principal commercial patent barriers have since expired, allowing generic development in the United States and other major jurisdictions.

A current applicant should distinguish between:

• Statutory FDA exclusivity, which ended years ago;
• Listed patents, which must be checked against the current Orange Book;
• Unlisted process or manufacturing patents;
• Local patent rights in countries where the product launched later;
• Regulatory data protection in jurisdictions outside the United States.

For adefovir dipivoxil, the practical U.S. barrier is generally product economics and market demand, not remaining brand exclusivity.

Are there Paragraph IV challenges for adefovir dipivoxil?

Paragraph IV litigation is unlikely to be a material current U.S. market issue for adefovir dipivoxil. The product has been generic for years, and the original patent estate is no longer a significant barrier to ordinary tablet approval.

The more relevant ANDA issues are:

• Whether an applicant can reference the correct listed drug;
• Whether the reference product remains commercially available or requires an authorized generic or discontinued-product strategy;
• Whether the formulation is sufficiently similar for pharmaceutical equivalence;
• Whether dissolution and impurity profiles support biowaiver or bioequivalence requirements;
• Whether the applicant can justify differences in excipient composition.

A generic launch would normally occur through one of three routes:

1. Standard ANDA submission against the listed drug.
2. A market-specific submission where the U.S. product is commercially inactive.
3. A regional generic or branded-generic filing in Asia, Latin America, the Middle East, or Africa.

What commercial opportunities exist for adefovir dipivoxil?

Low-cost generic tablets

The largest opportunity is a low-cost 10 mg tablet for markets where adefovir remains embedded in treatment protocols. Manufacturing should focus on high-volume compression, low-cost excipients, and a stable supply of qualified API.

Emerging-market branded generics

Adefovir has retained commercial relevance in markets with large hepatitis B populations, particularly parts of Asia. A branded generic can compete through:

• Lower price than tenofovir-based regimens;
• Reliable local distribution;
• Government tender participation;
• Smaller pack sizes;
• Hospital and clinic supply contracts;
• Local-language patient materials.

The pricing ceiling is low, and the product should not be positioned as a premium antiviral absent new clinical data.

Lactose-free or excipient-restricted tablets

A lactose-free product can differentiate within generic portfolios, especially for hospitals and patients with excipient sensitivities. The commercial value is incremental rather than transformative.

Pediatric and dispersible presentations

A pediatric dispersible tablet, granule, or oral suspension could address patients unable to swallow tablets. The opportunity is technically more attractive than a new adult formulation but carries added stability, taste-masking, dosing-accuracy, and pediatric regulatory requirements.

A liquid product must address:

• Hydrolytic and chemical stability;
• Dose uniformity after shaking;
• Microbial preservation;
• Palatability;
• Packaging compatibility;
• Safe administration for patients with renal impairment.

Combination products

Adefovir dipivoxil combinations with other hepatitis B agents have limited commercial potential because combining agents with overlapping antiviral activity or renal liabilities may not offer a strong clinical advantage. A fixed-dose combination could be relevant in a specific national guideline or adherence program, but it would require clinical and regulatory justification.

How does adefovir dipivoxil compare with competing hepatitis B drugs?

Product	Main advantage	Main limitation	Commercial effect on adefovir
Adefovir dipivoxil	Established, low-cost, once daily	Renal toxicity and weaker contemporary positioning	Baseline generic price competitor
Tenofovir disoproxil fumarate	Strong antiviral activity and broad use	Renal and bone monitoring concerns	Usually a stronger substitute
Tenofovir alafenamide	Lower systemic tenofovir exposure and improved renal/bone profile	Higher cost and newer product economics	Reduces premium-market demand for adefovir
Entecavir	Strong efficacy and long-standing HBV use	Resistance concerns in some treatment histories	Competes for first-line and maintenance use
Pegylated interferon	Finite treatment course in selected patients	Injectable and poorly tolerated	Different treatment segment

Adefovir’s commercial position is strongest where treatment cost dominates and where clinicians continue existing therapy in virologically suppressed patients. Its position is weakest in new-treatment markets governed by guidelines that prioritize tenofovir or entecavir.

What manufacturing and intellectual-property barriers remain?

The technical barriers are manageable but real:

• Low-dose content uniformity
• API particle-size control
• Oxidative and hydrolytic impurity monitoring
• Tablet dissolution after scale-up
• Lubricant sensitivity
• Film-coating reproducibility
• Stability in hot and humid climates
• Reliable API sourcing
• Compliance with current elemental impurity and nitrosamine expectations

The API supply chain is more important than formulation IP. A manufacturer with a qualified source of high-purity adefovir dipivoxil, validated impurity controls, and low-cost compression capacity can compete effectively even without a differentiated formulation.

What is the patent strength of adefovir dipivoxil today?

Adefovir dipivoxil has weak current patent strength as a conventional generic product. The original compound and prodrug patents are historical assets, and the original Hepsera exclusivity period has ended. Any residual value would depend on a new, patentable formulation, manufacturing process, delivery system, or clinically supported combination.

A new patent strategy would need to produce a measurable advantage, such as:

• Improved renal safety through altered exposure;
• Better pediatric administration;
• Enhanced stability in tropical climates;
• Reduced tablet burden;
• A validated fixed-dose combination;
• A novel dispersible or multiparticulate dosage form.

A minor excipient substitution alone is unlikely to provide meaningful enforceable protection unless it creates an unexpected technical effect supported by comparative data.

Key Takeaways

• Adefovir dipivoxil is a mature, off-patent small-molecule HBV product.
• The principal opportunity is low-cost generic or branded-generic supply in price-sensitive markets.
• Hepsera’s reference formulation uses lactose, pregelatinized starch, croscarmellose sodium, magnesium stearate, talc, and a hypromellose-based film coat.
• Low-dose content uniformity, dissolution, lubrication control, and stability are the key formulation risks.
• Lactose-free, pediatric dispersible, and tropical-stability presentations offer the clearest differentiation opportunities.
• Biosimilar risk is irrelevant; generic substitution is the relevant competitive threat.
• Tenofovir and entecavir limit premium-market potential.
• New patent value would require a technically meaningful formulation, delivery, manufacturing, or combination innovation.

FAQs

Is adefovir dipivoxil still commercially viable?

Yes, but mainly as a low-cost generic or branded generic in markets where chronic hepatitis B treatment remains price sensitive and adefovir remains accepted in clinical practice.

Can adefovir dipivoxil be formulated as a lactose-free tablet?

Yes. Microcrystalline cellulose, mannitol, or dibasic calcium phosphate can replace lactose, subject to dissolution, compression, stability, and bioequivalence evaluation.

Does adefovir dipivoxil have biosimilar competition?

No. Adefovir dipivoxil is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, not biosimilar regulation.

Is adefovir dipivoxil suitable for a controlled-release formulation?

The commercial case is weak. The approved product is once daily, and controlled release would add development cost without a clear clinical benefit.

What is the most attractive new dosage form for adefovir dipivoxil?

A pediatric dispersible tablet or stable oral granule is more commercially defensible than an adult extended-release product, provided palatability, dose accuracy, and stability can be demonstrated.

References

1. Gilead Sciences, Inc. (2022). Hepsera (adefovir dipivoxil) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2002). Hepsera approval history and NDA 021449. FDA.

3. European Association for the Study of the Liver. (2017). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 67(2), 370-398.

4. World Health Organization. (2024). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. WHO.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.